DDInter998 DDInter703
Ivermectin is a semi-synthetic antiparasitic medication derived from avermectins, a class of highly-active broad-spectrum antiparasitic agents isolated from the fermentation products of _Streptomyces avermitilis_. Ivermectin itself is a mixture of two avermectins, comprising roughly 90% 5-O-demethyl-22,23-dihydroavermectin A<sub>1a</sub> (22,23-dihydroavermectin B<sub>1a</sub>) and 10% 5-O-demethyl-25-de(1-methylpropyl)-22,23-dihydro­-25-(1-methylethyl)avermectin A<sub>1a</sub> (22,23-dihydroavermectin B<sub>1b</sub>). Ivermectin is mainly used in humans in the
Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 100mg tablets in the treatment of adult HIV-1 infection documented to be resistant to therapy with other NNRTIs and antiretroviral agents. On March 26, 2012, approval was extended for use in treatment-experienced pediatric patients 6 to 18 years of age, weighing at least 16 kg. Etravarine must always be used in combination with other antiretroviral drugs. Etravirine exerts its effects via direct inhibition of the reverse transcriptase enzyme of human immunodeficiency virus type 1 (HIV-1), and consequently blocks DNA-dependent and RNA-dependent polymerase activity. Etravirine does not inhibit human DNA polymerase alpha, beta or gamma. Common side effects of use include mild to moderate rash within the first 6 weeks of therapy, nausea, diarrhea and peripheral neuropathy. Patients are advised to immediately contact their healthcare provider if a rash develops. In 2009, postmarketing case reports of Stevens-Johnson Syndrome, toxic epidermal necrolysis, erythema multiforme, and other hypersensitivity reactions lead to a revision of etravirine's "Warnings and Precautions," as well as notification of health care providers. In 2013, reports of Autoimmune disorders (such as Graves’ disease, polymyositis, and Guillain-Barré syndrome) in the setting of immune reconstitution, as well as more in depth information about the development of rashes in patients taking etravirine, lead to a modification of etravirine's monograph.
Ivermectin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Etravirine
Ivermectin {u} (Compound) causes {v} (Side Effect) Rash
Rash {u} (Side Effect) is caused by {v} (Compound) Etravirine
Ivermectin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Rilpivirine
Rilpivirine {u} (Compound) resembles {v} (Compound) Etravirine
Ivermectin {u} (Compound) causes {v} (Side Effect) Rash
Rash {u} (Side Effect) is caused by {v} (Compound) Rilpivirine
Rilpivirine {u} (Compound) resembles {v} (Compound) Etravirine
Ivermectin {u} (Compound) causes {v} (Side Effect) Anorexia
Anorexia {u} (Side Effect) is caused by {v} (Compound) Bexarotene
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Etravirine
Ivermectin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Ranitidine
Ranitidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Etravirine
Ivermectin {u} (Compound) causes {v} (Side Effect) Stevens-Johnson syndrome
Stevens-Johnson syndrome {u} (Side Effect) is caused by {v} (Compound) Sunitinib
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etravirine
Ivermectin {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Sunitinib
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etravirine
Ivermectin {u} (Compound) upregulates {v} (Gene) HAX1
HAX1 {u} (Gene) interacts with {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Etravirine
Ivermectin {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Apixaban
Apixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etravirine
Ivermectin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Etravirine (Compound)
Ivermectin (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Etravirine (Compound)
Ivermectin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Rilpivirine (Compound) and Rilpivirine (Compound) resembles Etravirine (Compound)
Ivermectin (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Rilpivirine (Compound) and Rilpivirine (Compound) resembles Etravirine (Compound)
Ivermectin (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Bexarotene (Compound) and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Etravirine
Ivermectin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ranitidine (Compound) and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Etravirine
Ivermectin (Compound) causes Stevens-Johnson syndrome (Side Effect) and Stevens-Johnson syndrome (Side Effect) is caused by Sunitinib (Compound) and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Ivermectin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Sunitinib (Compound) and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Ivermectin (Compound) upregulates HAX1 (Gene) and HAX1 (Gene) interacts with ABCB1 (Gene) and ABCB1 (Gene) is bound by Etravirine (Compound)
Ivermectin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Apixaban (Compound) and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Etravirine